Interview with Dr James Garner, CEO of Kazia Therapeutics
-
Regulatory July 5, 2022Vivesto winds down its activities in Russia
-
Regulatory June 30, 2022Vivesto appoints Robert Maiorana as acting CFO
-
Regulatory June 13, 2022Vivesto and CEO Francois Martelet have agreed on ending the employment relationship
Vivesto published its Q1 2022 report on May 25, 2022, at 08.00 am CET.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program
This #MensHealthWeek have a look at this campaign by @menshealthforum all about how to carry out a MAN-MOT. Your car gets one regularly so why not all men? This article shows how to do your own and help early diagnosis of Prostate cancer.
Read more here:
DIY Man MOT
Your car gets one regularly but what about you? No, not a parking ticket, an MOT. Giving your body a once-over...
bit.ly
Today we published our Q1 #Financial #Results.
In a challenging financial climate, we were pleased to successfully raise SEK 151m during the quarter and report operational progress on several fronts.
#oncology #biotech
Interim report for the period January 1, 2022 – March 31, 2022 - Vivesto
SIGNIFICANT EVENTS DURING THE FIRST QUARTER
bit.ly